What the FDA labels say about taking them together
Rifampin and sofosbuvir/velpatasvir/voxilaprevir
Sofosbuvir/velpatasvir/voxilaprevir's FDA label of July 14, 2025 names rifampin in its contraindications section; the rifampin label PlainMeds reads does not name sofosbuvir/velpatasvir/voxilaprevir. The sofosbuvir/velpatasvir/voxilaprevir label: “Coadministration with rifampin is contraindicated.”
Check it at the source: the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.); the sofosbuvir/velpatasvir/voxilaprevir FDA label on DailyMed (effective July 14, 2025, Gilead Sciences, Inc.).
What does the rifampin label say about sofosbuvir/velpatasvir/voxilaprevir?
Rifampin's label (effective February 11, 2026) does not name sofosbuvir/velpatasvir/voxilaprevir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
What does the sofosbuvir/velpatasvir/voxilaprevir label say about rifampin?
Sofosbuvir/velpatasvir/voxilaprevir label, contraindicationsCONTRAINDICATIONS VOSEVI is contraindicated with rifampin [see Drug Interactions (7.3), and Clinical Pharmacology (12.3) ].
Sofosbuvir/velpatasvir/voxilaprevir label, drug interactionsConcomitant Drug Class/Drug Name: rifampin; Effect on Concentration ↓ = decrease, ↑ = increase.: ↓ sofosbuvir ↓ velpatasvir ↑ voxilaprevir (single dose) ↓ voxilaprevir (multiple dose); Clinical Effect/Recommendation: Coadministration with rifampin is contraindicated [see ].
Source: FDA drug label (Vosevi), Gilead Sciences, Inc., effective July 14, 2025 (SPL set 17ffc094-8ca7-45d2-80d8-fd043bc9a221), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rifampin | Sofosbuvir/velpatasvir/voxilaprevir | |
|---|---|---|
| Labeled for | n/a | Hepatitis C |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.679 per capsule 300 mg capsule | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once